{"id":"W4281951137","doi":"10.1016/s0140-6736(22)00688-2","title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","year":2022,"lang":"en","type":"article","venue":"The Lancet","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":297,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; University Hospital; Western University","funders":"Seres Therapeutics; Janssen Scientific Affairs; Crohn's and Colitis Foundation; Gilead Sciences; GlaxoSmithKline; Pfizer; Genentech; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Ustekinumab; Adalimumab; Clinical endpoint; Crohn's disease; Internal medicine; Clinical trial; Population; Randomized controlled trial; Intention-to-treat analysis; Adverse effect; Randomization; Maintenance therapy; Disease; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002541332,0.0002141589,0.0002661336,0.00004263206,0.0002381718,0.00003921664,0.0002533451,0.00005838606,0.00001629868],"category_scores_gemma":[0.0000772568,0.0001481729,0.00007071788,0.00009444002,0.0000731834,0.00001426934,0.0001195814,0.0001443886,0.000001210334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007316457,"about_ca_system_score_gemma":0.00009761156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001974709,"about_ca_topic_score_gemma":0.00005981372,"domain_scores_codex":[0.9986005,0.0002315815,0.0002005619,0.0004408094,0.0001642416,0.0003622528],"domain_scores_gemma":[0.9992391,0.00004924876,0.0001413529,0.0003705515,0.00008942297,0.0001103186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9944,0.0004480848,0.0003123635,0.00001130293,0.0001268522,0.00002444899,0.00026909,0.001850498,0.000190858,0.00005772038,0.0004884637,0.001820358],"study_design_scores_gemma":[0.9482022,0.002057668,0.04509808,0.00001024655,0.00004844572,0.000001027217,0.000302955,0.0003737207,0.000171993,0.00007497404,0.003357371,0.0003013056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935802,0.0001051672,0.0002248387,0.0003010317,0.000252869,0.005001969,0.0004722098,0.00001623984,0.00004542361],"genre_scores_gemma":[0.9960213,0.00006371827,0.0001596998,0.0004338098,0.0003149013,0.002444349,0.0004848563,0.00002658077,0.00005075153],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04619774,"threshold_uncertainty_score":0.6042317,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04148110825086292,"score_gpt":0.2987136586084228,"score_spread":0.2572325503575599,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}